EMILY BOYDSTON: Open Payments
NPI 1194445361 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$685 in 20 payments from 6 companies in 2025. Trend: 2023 $458 · 2024 $891 · 2025 $685
Food & beverage: $685
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $314 |
| GENZYME CORPORATION | 4 | $179 |
| Regeneron Healthcare Solutions, Inc. | 2 | $72 |
| Smith+Nephew, Inc. | 1 | $59 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Amgen Inc. | 1 | $20 |
Products named: NUCALA, DUPIXENT, TEZSPIRE, TULA.
Industry payments across CA — which companies pay providers there.
